These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 21537346)

  • 21. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of reducing the prostate-specific antigen threshold and including isoform reflex tests on the performance characteristics of a prostate-cancer detection programme.
    Roddam AW; Hamdy FC; Allen NE; Price CP;
    BJU Int; 2007 Sep; 100(3):514-7. PubMed ID: 17542987
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of obesity and lower serum prostate-specific antigen levels on prostate-cancer screening results in American men.
    Culp S; Porter M
    BJU Int; 2009 Nov; 104(10):1457-61. PubMed ID: 19522868
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
    Heijnsdijk EA; Denham D; de Koning HJ
    Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prostate cancer: who to screen, and what the results mean.
    Small EJ
    Geriatrics; 1993 Dec; 48(12):28-30, 35-8. PubMed ID: 7504646
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
    Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
    Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate-Specific Antigen (PSA)-Based Population Screening for Prostate Cancer: An Economic Analysis.
    Tawfik A
    Ont Health Technol Assess Ser; 2015; 15(11):1-37. PubMed ID: 26366237
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of prostate health index for prostate cancer detection in Chinese men.
    Teoh JY; Leung CH; Wang MH; Chiu PK; Yee CH; Ng CF; Wong MC
    Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):615-621. PubMed ID: 32606435
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost implications of PSA screening differ by age.
    Rao K; Liang S; Cardamone M; Joshu CE; Marmen K; Bhavsar N; Nelson WG; Ballentine Carter H; Albert MC; Platz EA; Pollack CE
    BMC Urol; 2018 May; 18(1):38. PubMed ID: 29743049
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost analyses of prostate cancer screening: frameworks for discussion. Investigators of the American Cancer Society-National Prostate Cancer Detection Project.
    Littrup PJ; Goodman AC; Mettlin CJ; Murphy GP
    J Urol; 1994 Nov; 152(5 Pt 2):1873-7. PubMed ID: 7523734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
    Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
    Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prospective Assessment of an innovative test for prostate cancer screening using the VITA process model framework.
    Gantner-Bär M; Meier F; Kolominsky-Rabas P; Djanatliev A; Metzger A; Voigt W; Prokosch HU; Sedlmayr M
    Stud Health Technol Inform; 2014; 205():236-40. PubMed ID: 25160181
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Can PSA Reflex Algorithm be a valid alternative to other PSA-based prostate cancer screening strategies?
    Caldarelli G; Troiano G; Rosadini D; Nante N
    Ann Ig; 2017; 29(3):218-222. PubMed ID: 28383613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.
    Coley CM; Barry MJ; Fleming C; Fahs MC; Mulley AG
    Ann Intern Med; 1997 Mar; 126(6):468-79. PubMed ID: 9072935
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic evaluation of prostate cancer screening test as a national cancer screening program in South Korea.
    Shin S; Kim YH; Hwang JS; Lee YJ; Lee SM; Ahn J
    Asian Pac J Cancer Prev; 2014; 15(8):3383-9. PubMed ID: 24870726
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Beyond the PSA: The hidden costs of screening in prostate cancer.
    Sanyal C; Ragavan MV
    Cancer; 2024 Oct; 130(19):3272-3274. PubMed ID: 39012908
    [No Abstract]   [Full Text] [Related]  

  • 37. Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality.
    Etzioni R; Durand-Zaleski I; Lansdorp-Vogelaar I
    J Natl Cancer Inst Monogr; 2013; 2013(46):117-23. PubMed ID: 23962515
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Re: Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
    Noordzij MA; Blanker MH
    J Natl Cancer Inst; 2015 Jun; 107(6):djv110. PubMed ID: 25888716
    [No Abstract]   [Full Text] [Related]  

  • 39. Re: Cost-Effectiveness of Prostate Cancer Screening: A Simulation Study Based on ERSPC Data.
    Taneja SS
    J Urol; 2015 Jul; 194(1):113-4. PubMed ID: 26088223
    [No Abstract]   [Full Text] [Related]  

  • 40. Free PSA for detecting prostate cancer.
    Peven DR
    JAMA; 1998 Dec; 280(21):1825; author reply 1826. PubMed ID: 9846768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.